Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Automated functionalization of lipid nanoparticles for targeted drug delivery and in vivo production of CAR T cells.

FY 2019-20

Summary
"Nanomedicine has transformed drug delivery. Rather than relying on the passive distribution of a therapeutic (antibodies, vaccines, enzymes, nucleic acids) throughout the body to eventually reach the targeted tissue, researchers can now load therapeutics into nanoparticles capable of delivering them to a specific target site. However, the scope of nanomedicine is limited by complicated and expensive manufacturing logistics, thus limiting availability of nanomedicines to researchers and clinicians alike. A potential application of nanomedicine is improving chimeric antigen receptor (CAR) T cell therapy, a cancer treatment that reprograms a patient's immune system (T cells) to destroy tumours. Much of the work to date has relied on modifying T cells outside of the body: an expensive and risky process. Instead, nanoparticles can be used to target and reprogram T cells in the patient's body, circumventing the need for expensive and difficult T cell isolation. In my research, I aim to overcome these challenges by developing molecular tools for simplified, portable, and on-demand production and incorporation of biological therapeutics in to nanoparticles. To demonstrate the capability of this technology, I will apply these tools to produce nanoparticles capable of generating CAR T cells inside rather than outside the body. By developing tools for inexpensive, portable and on-demand production of nanomedicines, this research has the potential to i) accelerate nanomedicine research by improving availability to researchers and ii) ensure that the therapeutic benefits of nanomedicine can be delivered to all patients in remote and low resource settings in Canada and globally. "
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428964
Name
Matthews Quinn E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Automated functionalization of lipid nanoparticles for targeted drug delivery and in vivo production of CAR T cells.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomolecule Manufacturing; Car T Cells; Cell-Free Protein Synthesis; Cutting Edge; Genome Engineering; Improved Healthcare Access; Molecular Tools; Nanomedicine; Synthetic Biology; Targeted Drug Delivery
Abstract
"Nanomedicine has transformed drug delivery. Rather than relying on the passive distribution of a therapeutic (antibodies, vaccines, enzymes, nucleic acids) throughout the body to eventually reach the targeted tissue, researchers can now load therapeutics into nanoparticles capable of delivering them to a specific target site. However, the scope of nanomedicine is limited by complicated and expensive manufacturing logistics, thus limiting availability of nanomedicines to researchers and clinicians alike. A potential application of nanomedicine is improving chimeric antigen receptor (CAR) T cell therapy, a cancer treatment that reprograms a patient's immune system (T cells) to destroy tumours. Much of the work to date has relied on modifying T cells outside of the body: an expensive and risky process. Instead, nanoparticles can be used to target and reprogram T cells in the patient's body, circumventing the need for expensive and difficult T cell isolation. In my research, I aim to overcome these challenges by developing molecular tools for simplified, portable, and on-demand production and incorporation of biological therapeutics in to nanoparticles. To demonstrate the capability of this technology, I will apply these tools to produce nanoparticles capable of generating CAR T cells inside rather than outside the body. By developing tools for inexpensive, portable and on-demand production of nanomedicines, this research has the potential to i) accelerate nanomedicine research by improving availability to researchers and ii) ensure that the therapeutic benefits of nanomedicine can be delivered to all patients in remote and low resource settings in Canada and globally. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Matthews, Quinn E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~